Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pingfeng Bishu Capsule is a Traditional Chinese Medicine (TCM) product developed and manufactured by Qinghai Plant Pharmaceutical Co., Ltd. It is primarily indicated for the treatment of perennial allergic rhinitis. The formulation is based on the classic Jade Windscreen (Yu Ping Feng) formula, typically containing ingredients such as *Astragalus membranaceus*, *Atractylodes macrocephala*, and *Saposhnikovia divaricata*, often supplemented with other herbs like *Magnolia biondii* and *Xanthium sibiricum* to target nasal symptoms. Its mechanism of action involves immunomodulation, specifically the regulation of Th1/Th2 balance and the reduction of IgE levels, alongside anti-inflammatory effects that alleviate nasal congestion, sneezing, and pruritus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pingfeng Bishu Capsule.